In:
Oncology, S. Karger AG, Vol. 99, No. 5 ( 2021), p. 300-309
Abstract:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Unresectable cholangiocarcinoma has a poor prognosis and treatment options are limited. Combined systemic and intrahepatic chemotherapy may improve local control and enable downsizing. The aim of this study was to determine the maximum tolerated dose (MTD) of intravenous gemcitabine combined with intravenous cisplatin and hepatic arterial infusion (HAI) with floxuridine (FUDR) in patients with unresectable intrahepatic or hilar cholangiocarcinoma. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Twelve patients were treated within a 3 + 3 dose escalation algorithm with 600, 800, or 1,000 mg/m 〈 sup 〉 2 〈 /sup 〉 gemcitabine and predefined doses of cisplatin 25 mg/m 〈 sup 〉 2 〈 /sup 〉 on days 1 and 8, q21, for 4 cycles, and FUDR 0.2 mg/kg on days 1–14 as continuous HAI, q28, for 3 cycles. Safety and toxicity as well as resectability rates after 3 months and preliminary survival data are reported. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The determined MTD for gemcitabine was 800 mg/m 〈 sup 〉 2 〈 /sup 〉 . Dose limiting toxicities were neutropenic fever and biliary tract infections. In total, 27% of the patients showed partial remission and 73% stable disease. Although none of the patients achieved resectability after 3 months, the 3-year overall survival rate was 33%, median overall survival 23.9 months (range 1–49), and median progression-free survival 10.1 months (range 2–40). 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Intravenous gemcitabine/cisplatin plus HAI-FUDR is feasible and appears effective for disease control. Larger prospective studies evaluating this triplet combination are warranted.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2021
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink
